The policy identifies numerous devices and indications as experimental, investigational, or unproven. Examples explicitly listed include FES of the upper extremities (e.g., NESS H200/Handmaster) and a wide range of other applications for FES/NMES such as Bell’s palsy, cerebral palsy, COPD, congestive heart failure, erectile dysfunction, general muscle strengthening in healthy individuals, and improvement of ambulatory function in progressive diseases (see enumerated list in the scope). These device/indication groupings are treated as lacking established effectiveness in the evidence base and therefore are not supported for routine coverage.
The policy also lists multiple specific devices and device classes considered unproven, for example: AxioBionics wearable NMES for hemiplegia, Cala Trio (wrist-worn peripheral nerve stimulation), EMG-triggered NMES (Care ETS), implanted FES for gait after stroke, PoNS (trans‑lingual neurostimulation), TOMAC, Walkasins, wearable geko NMES devices, and a variety of FES exercise systems (MyoCycle, RT-series, SpectraSTIM). Many of these technologies are described as having insufficient or mixed evidence to establish long‑term functional benefit or to justify routine DME coverage.
Where the document details indications judged investigational, it notes either small/uncontrolled studies, absence of durable functional outcomes, or inconsistent trial results supporting that determination. Providers should therefore plan prior authorization or coverage requests for these devices on the expectation that a strong evidence package or enrollment in an approved clinical trial will be required to justify use.